• Explore /
  • Poster
  • / Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with <i>BRAF</i> V600-mutant melanoma.

Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma.

Abstract Poster

Authors

null

Paul B. Chapman

Memorial Sloan Kettering Cancer Center, New York, NY

Paul B. Chapman , Paolo Antonio Ascierto , Dirk Schadendorf , Jean Jacques Grob , Antoni Ribas , Felix Kiecker , Caroline Dutriaux , Lev V. Demidov , Celeste Lebbe , Piotr Rutkowski , Christian U. Blank , Ralf Gutzmer , Michael Millward , Richard Kefford , Yingjie Huang , Ying Zhang , Matthew Squires , Bijoyesh Mookerjee , Axel Hauschild

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT01153763; NCT01227889

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9526)

DOI

10.1200/JCO.2017.35.15_suppl.9526

Abstract #

9526

Poster Bd #

134

Abstract Disclosures

Similar Posters

First Author: Rahima Jamal

First Author: Evan Hersh

First Author: Kristine Peregrino Lacuna

First Author: Howland E. Crosswell